MECHANISMS OF SIGNAL TRANSDUCTION
CD44-initiated Cell Spreading Induces Pyk2 Phosphorylation, Is Mediated by Src Family Kinases, and Is Negatively Regulated by CD45*

https://doi.org/10.1074/jbc.M100158200Get rights and content
Under a Creative Commons license
open access

CD44 is a cell adhesion molecule implicated in leukocyte adhesion and migration, co-stimulation of T cells, and tumor metastasis. CD45 is a leukocyte-specific protein tyrosine phosphatase that dephosphorylates the Src family kinases, Lck and Fyn, in T cells. Positive regulation of Lck by CD45 is required for its effective participation in T cell receptor signaling events. Here, immobilized CD44 antibody induced a distinctive cell spreading in CD45, but not CD45+, T cells, and this correlated with the induction of tyrosine-phosphorylated proteins. Two focal adhesion family kinases, Pyk2 and, to a lesser extent, FAK were inducibly phosphorylated, as was a potential substrate, Cas. CD44-mediated cell spreading and induced tyrosine phosphorylation were prevented by the Src family kinase inhibitor, PP2. Furthermore, 2-fold more Lck associated with CD44 in the low density sucrose fraction from CD45 T cells compared with CD45+ T cells, suggesting that CD45 may regulate the association of Lck with CD44 in this fraction. Therefore, in CD45 T cells, CD44 signaling is mediated by Src family kinases, and this leads to Pyk2 phosphorylation, cytoskeletal changes, and cell spreading. This implicates CD45 in the negative regulation of Src family kinase-mediated CD44 signaling leading to T cell spreading.

Cited by (0)

Published, JBC Papers in Press, May 21, 2001, DOI 10.1074/jbc.M100158200

*

This work was supported by funds from the National Science and Engineering Research Council of Canada and from the Medical Research Council of Canada.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Current address: Kinetek Pharmaceuticals Inc., 1779 West 75th Ave., Vancouver, British Columbia V6P 6P2, Canada.